Searched for: subject%3A%22Drug%255C%2Btherapy%22
(1 - 18 of 18)
document
Suchowerska, A.K. (author), Stokman, G. (author), Palmer, J.T. (author), Coghlan, P.A. (author), Pieterman, E.J. (author), Keijzer, N. (author), Lambert, G. (author), Chemello, K. (author), Jaafar, A.K. (author), Parmar, J. (author), Yan, L. (author), Tong, Y. (author), Mu, L. (author), Princen, H.M.G. (author), Bonnar, J. (author), Evison, B.J. (author)
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor for lysosomal degradation. As the interaction promotes elevated plasma LDL-C levels, and therefore a predisposition to...
article 2022
document
Pouwer, M.G. (author), Pieterman, E.J. (author), Worms, N. (author), Keijzer, N. (author), Jukema, J.W. (author), Gromada, J. (author), Gusarova, V. (author), Princen, H.M.G. (author)
Atherosclerosis-related cardiovascular disease causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocumab or evinacumab-monoclonal...
article 2020
document
van der Tuin, S.J. (author), Kühnast, S. (author), Berbée, J. (author), Verschuren, L. (author), Pieterman, E.J. (author), Havekes, L.M. (author), van der Hoorn, J.W. (author), Rensen, P.C. (author), Jukema, J.W. (author), Princen, H.M. (author), Willems van Dijk, K. (author), Wang, Y. (author)
Recently, we showed in APOE*3-Leiden.CETP mice that anacetrapib attenuated atherosclerosis development by reducing (V)LDL-C rather than by raising HDL-C. Here, we investigated the mechanism by which anacetrapib reduces (V)LDL-C and whether this effect was dependent on the inhibition of CETP. APOE*3-Leiden.CETP mice were fed a Western type diet...
article 2015
document
Hellgren, M. (author), Conard, J. (author), Norris, L. (author), Kluft, C. (author), TNO Kwaliteit van Leven (author)
Objective: To study cardiovascular risk markers in women taking estradiol/trimegestone or estradiol/dydrogesterone. Design: Multicenter, randomized, prospective, double-blind study of 184 healthy post-menopausal women randomized to 6 cycles of either estradiol (2 mg) + trimegestone (0.5 mg) (T-group) or estradiol (2 mg) + dydrogesterone (10 mg) ...
article 2009
document
Kubben, F.J.G.M. (author), Sier, C.F.M. (author), Schram, M. (author), Witte, T.A.M.C. (author), Veenendaal, R.A. (author), van Duijn, W. (author), Verheijen, J.H. (author), Hanemaaijer, R. (author), Lamers, C.B.H.W. (author), Verspaget, H.W. (author), TNO Kwaliteit van Leven (author)
Background: Helicobacter pylori gastritis is recognized as an important pathogenetic factor in peptic ulcer disease and gastric carcinogenesis, and is accompanied by strongly enhanced gastric mucosal matrix metalloproteinase-9 (MMP-9) levels. Aim: This study was performed to investigate whether H. pylori-affected gastric mucosal MMP-2 and MMP-9...
article 2007
document
Valstar, D.L. (author), Schijf, M.A. (author), Arts, J.H.E. (author), Kuper, C.F. (author), Nijkamp, F.P. (author), Storm, G. (author), Bloksma, N. (author), Henricks, P.A.J. (author), TNO Kwaliteit van Leven (author)
Occupational exposure to low molecular weight chemicals, like trimellitic anhydride (TMA), can result in occupational asthma. Alveolar macrophages (AMs) are among the first cells to encounter these inhaled compounds and were previously shown to affect TMA-induced asthma-like symptoms in the Brown Norway rat (Valstar et al., Toxicol. Appl....
article 2006
document
TNO Kwaliteit van Leven (author), Trion, A. (author), Maat, M.de (author), Jukema, W. (author), Maas, A. (author), Offerman, E. (author), Havekes, L. (author), Szalai, A. (author), Laarse, A.V.D. (author), Princen, H. (author), Emeis, J. (author)
We investigated the pleiotropic effects of a calcium antagonist (amlodipine) on early atherosclerosis development in the presence and absence of an HMG-CoA-reductase inhibitor (atorvastatin) in apolipoprotein E*3-Leiden/human C-reactive protein (E3L/CRP) transgenic mice. Male E3L/CRP transgenic mice were fed a cholesterol-containing diet either...
article 2006
document
van der Greef, J. (author), TNO Kwaliteit van Leven (author)
The concept of systems-based strategies in medicine is emerging, with systems pathology guiding an understanding of the multidimensional aspects of disease system fingerprints and systems pharmacology providing insight into dynamic system responses upon (multiple) drug perturbations. Knowledge of the changes of system characteristics during...
article 2005
document
van Helden, H.P.M. (author), van de Meent, D. (author), Oostdijk, J.P. (author), Joosen, M.J.A. (author), van Esch, J.H.M. (author), Hammer, A.H. (author), Diemel, R.V. (author)
Airborne exposure to lung-toxic agents may damage the lung surfactant system and epithelial and endothelial cells, resulting in a life-threatening pulmonary edema that is known to be refractory to treatment. The aim of this study was to investigate in rats (1) the respiratory injury caused by nose-only exposure to perfluoroisobutene (PFIB), and ...
article 2004
document
TNO Preventie en Gezondheid (author), Landewé, R. (author), Geusens, P. (author), Boers, M. (author), van der Heijde, D. (author), Lems, W. (author), te Koppele, J. (author), van der Linden, S. (author), Garnero, P. (author)
Objective. To investigate in a randomized clinical trial setting with an aggressive combination-therapy arm and a mild-monotherapy arm, whether therapy-induced changes in urinary C-terminal crosslinking telopeptide of type I collagen (CTX-I) and type II collagen (CTX-II) predict 5-year radiographic progression in patients with rheumatoid...
article 2004
document
Delsing, D.J.M. (author), Jukema, J.W. (author), van de Wiel, M.A. (author), Emeis, J.J. (author), van der Laarse, A. (author), Havekes, L.M. (author), Princen, H.M.G. (author), Gaubius Instituut TNO (author)
This study was designed to investigate the potential antiatherosclerotic effects of the calcium antagonist amlodipine as compared with the HMG-CoA reductase inhibitor atorvastatin and the combination of both in ApoE*3-Leiden transgenic mice. Four groups of 15 ApoE*3-Leiden mice were put on a high-cholesterol diet. One group received 0.002% (wt...
article 2003
document
Verhoeven, A.C. (author), Boers, M. (author), te Koppele, J.M. (author), van der Laan, W.H. (author), Markusse, H.M. (author), Geusens, P. (author), van der Linden, S. (author), Gaubius Instituut (author)
Objectives. Exploration of bone metabolism changes at different levels of disease activity, both with and without oral corticosteroid therapy, and prediction of changes in joint damage and bone density from the observed changes in markers of bone turnover. Methods. Data analysis from a randomized clinical trial with 155 rheumatoid arthritis (RA)...
article 2001
document
Buitendijk, S.E. (author)
In the 'Overview of the role of antibiotics in curtailing labour and early delivery'(ORACLE I)-trial in women with premature rupture of membranes, the use of erythromycin was found to be associated with a decrease in the primary composite outcome (neonatal death, chronic lung disease or major cerebral abnormality on ultrasound; p = 0.08) and in...
article 2001
document
Yudkin, J.S. (author), Panahloo, A. (author), Stehouwer, C. (author), Emeis, J.J. (author), Bulmer, K. (author), Mohamed-Ali, V. (author), Denver, A.E. (author), Gaubius Instituut TNO (author)
Aims/hypothesis. Improved glycaemic control might reduce both microvascular and macrovascular complications of Type II diabetes (non-insulin-dependent) mellitus. To explore such possible mechanisms, we investigated the effects of intensive treatment on markers of endothelial dysfunction and of acute phase activation, using both sulphonylureas...
article 2000
document
Centraal Instituut voor Voedingsonderzoek TNO TNO Preventie en Gezondheid (author), Pouwels, P.H. (author), Leer, R.J. (author), Boersma, W.J.A. (author)
Oral administration of lactobacilli evokes mucosal and systemic immune responses against epitopes associated with these organisms (Gerritse et al., 1990, 1991). The adjuvant function of different Lactobacillus species was investigated under the conditions of intraperitoneal (i.p.) injection or oral administration. After i.p. injection of...
article 1996
document
Banta, H.D. (author), Nederlands Instituut voor Praeventieve Gezondheidszorg TNO (author)
Assessing the value of health care interventions is more and more a concern of governments, clinicians, health insurance companies, policy makers, and the general public. One dimension of the outcomes of such interventions that has received relatively little attention until recently is quality of life. However, during the last decade, measuring...
article 1993
document
Sprengers, E.D. (author), Kluft, C. (author), Gaubius Instituut TNO (author)
Chemicals/CAS: fibrin, 9001-31-4; plasminogen activator inhibitor, 105844-41-5; plasminogen activator, 9039-53-6; Carrier Proteins; Glycoproteins; Plasminogen Activators, EC 3.4.21.-; Plasminogen Inactivators; Protease Inhibitors; protease-nexin
article 1987
document
Haverkate, F. (author), Nieuwenhuizen, W. (author), Gaubius Instituut TNO (author)
Chemicals/CAS: calcium chloride, 10043-52-4; calcium, 7440-70-2; citric acid, 126-44-3, 5949-29-1, 77-92-9, 8002-14-0; edetic acid, 150-43-6, 60-00-4
article 1984
Searched for: subject%3A%22Drug%255C%2Btherapy%22
(1 - 18 of 18)